[HTML] thelancet.comFull View

[HTML][HTML] Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett… - …, 2022 - thelancet.com
Background There is significant interest in treatment de-escalation for human papillomavirus-
associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the …
被引用次数：12 相关文章
[HTML] sciencedirect.com

[HTML][HTML] Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett, M Shammas-Toma… - eBioMedicine, 2022 - Elsevier
Background There is significant interest in treatment de-escalation for human papillomavirus-
associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the …

Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett… - …, 2022 - cris.maastrichtuniversity.nl
Background There is significant interest in treatment de-escalation for human papillomavirus-
associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the …

Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background There is significant interest in treatment de-escalation for human papillomavirus-
associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the …

Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.

PYF Zeng, MJ Cecchini, JW Barrett… - Ebiomedicine, 2022 - europepmc.org
Background There is significant interest in treatment de-escalation for human papillomavirus-
associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the …

Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett… - …, 2022 - researchinformation.amsterdamumc …
Background: There is significant interest in treatment de-escalation for human
papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) …

Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett, M Shammas-Toma… - EBIOMEDICINE, 2022 - air.unipr.it
Background: There is significant interest in treatment de-escalation for human
papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) …

Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett… - EBIOMEDICINE, 2022 - air.unimi.it
Background: There is significant interest in treatment de-escalation for human
papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) …

Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.

P Zeng, M Cecchini, J Barrett, M Shammas-Toma… - 2022 - escholarship.org
BACKGROUND: There is significant interest in treatment de-escalation for human
papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) …
[HTML] nih.gov

[HTML][HTML] Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

PYF Zeng, MJ Cecchini, JW Barrett… - eBioMedicine, 2022 - ncbi.nlm.nih.gov
Background There is significant interest in treatment de-escalation for human papillomavirus-
associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the …